ZiP Diagnostics

Executive Summary

ZiP Diagnostics is an Australian biotechnology company developing low-cost, rapid point-of-care molecular and lateral-flow diagnostics for human, animal, and environmental infectious diseases. Founded in 2019 and based in Collingwood, Australia, the company’s integrated cartridge-instrument platforms deliver polymerase chain reaction (PCR)-comparable sensitivity in under 30 minutes, targeting respiratory, sexually transmitted, vector-borne, and livestock pathogens. With an employee count between 50 and 200, ZiP Diagnostics is positioned at the preclinical stage, leveraging proprietary technology to address critical gaps in infectious disease detection, particularly in resource-limited settings. The company’s dual focus on human and veterinary health, combined with environmental monitoring capabilities, broadens its addressable market and potential impact. By enabling rapid, accurate diagnosis at the point of care, ZiP Diagnostics could improve patient outcomes, reduce transmission, and enhance disease surveillance in both developed and emerging markets. The company’s innovative platform has the potential to disrupt traditional diagnostic paradigms, offering affordable, accessible solutions that meet the needs of diverse healthcare ecosystems. With strong foundational technology and a clear mission, ZiP Diagnostics is well-positioned to advance its pipeline through preclinical and clinical development, attracting strategic partnerships and investment to accelerate commercialization.

Upcoming Catalysts (preview)

• Q3 2026Series A or Series B Funding Round70% success
• Q4 2026Announcement of Strategic Partnership for Clinical Development60% success
• Q1 2027Submission of First Product for Regulatory Approval (e.g., CE Mark or TGA)50% success